# Shanghai UniXell Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-unixell-biotechnology

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Latest round: Angel (Aug 1, 2021)
- Investors on record: 2

## About

Based in Shanghai, China, and founded in 2021, Shanghai UniXell Biotechnology operates as a biotechnology company that develops cell therapies for the treatment of various diseases. In March 2022, Shanghai UniXell Biotechnology raised USD 31.5 million, co-led by new investors CDH Investments and Sherpa Venture Capital, with participation from other new investors Fosun Pharma and TF Capital. Returning and individual investors GL Ventures and Kunlun Capital Pte Ltd also participated in the round.

UniXell offers human pluripotent stem cell (hPSC) technology used for illness simulation and cell replacement therapy. The company develops a pipeline of cell therapies to treat tumors, rare diseases, and neurological disorders like Parkinson's disease, Alzheimer's disease, and stroke.

The company plans to use the March 2022 funding for research and development of pipeline products, the construction of clinical-grade cell product production facilities, and the beginning and advancement of clinical trials.

## Funding rounds

- Angel, Aug 1, 2021 — Kunlun Capital, GL Ventures

## Investors

- Kunlun Capital — Angel
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Angel